How to investigate a positive medical device sensitization test

A positive sensitization test should trigger a documented investigation and a review of release decisions. It does not establish how often patients will develop an allergy, but it is a biological safety signal that requires an explanation. Repeating the study until a negative result appears cannot resolve that signal.

A medical device biocompatibility sensitization investigation needs to answer three questions: Is the result scientifically valid? What material, chemical, or process could explain it? What evidence supports the next decision about the device? Keep these questions connected, because a technically valid study can reveal an unexpected manufacturing problem, while an apparently reassuring repeat can leave the original hazard unresolved.

Contain the issue and preserve the evidence

Open a quality investigation and identify the affected device configuration, manufacturing lot, material batches, and processing history. Place potentially affected unreleased product under appropriate control while the scope is assessed. If related devices have already been distributed, evaluate the finding through the applicable post-market and risk-management processes; a laboratory result alone does not determine whether field action is necessary.

Preserve retained devices, available extracts, raw study records, and relevant manufacturing samples. Coordinate storage with the laboratory because extract composition can change during storage. Capture the following information before production changes or sample disposal make reconstruction difficult:

• The exact article tested, including coatings, accessories, packaging contact, and sterilization status.
• Whether it represented the final finished device and the intended manufacturing process.
• Extraction conditions, extract preparation dates, storage conditions, and treatment details.
• Recent changes to suppliers, formulations, cleaning, assembly, sterilization, or packaging.
• The relationship between the tested samples and other potentially affected products.

Assign responsibilities across the laboratory, manufacturing, materials, and biological evaluation functions. The laboratory can explain the observed response, but it usually cannot determine which undocumented production change introduced a residue.

Determine exactly what “positive” means in this study

Obtain the full report and supporting records rather than relying on the result summary. Interpretation depends on the method, its acceptance criteria, and the nature of the response. Animal sensitization methods and non-animal approaches measure different biological events; their outputs should not be interpreted interchangeably.

For a guinea pig study, review individual challenge responses, their timing and persistence, control findings, and observations suggesting irritation. For a local lymph node assay, examine the response pattern alongside evidence of local irritation or systemic toxicity. For a non-animal approach, assess whether the extract and its constituents fall within the method’s applicability domain and whether interference could affect the readout.

The distinction between irritation and sensitization deserves particular attention. Irritation is direct tissue injury or inflammation; sensitization involves an immune response that may produce a reaction after subsequent exposure. Inflammation can complicate the interpretation of some sensitization studies, but describing a response as “probably irritation” is not enough to dismiss it. That explanation needs evidence from the study observations and method-specific interpretation.

Review protocol deviations, sample identity, equipment records, preparation calculations, and the required control performance. Evaluate historical control information where relevant to the method. A procedural error matters only if its likely effect on the result can be explained. A minor documentation omission does not automatically invalidate a positive finding.

Record the study’s validity and the biological interpretation separately. A study may be valid and positive, invalid for a documented reason, or inconclusive because an unresolved factor prevents reliable interpretation.

Check whether extraction changed the question being asked

Extraction is intended to make potentially releasable substances available for biological testing. It can also create an exposure that differs substantially from clinical use. Review the extraction vehicle, temperature, duration, surface-area or mass-to-volume calculation, and any cutting or disassembly against the device and the study’s purpose.

Some conditions deliberately exaggerate exposure. That alone does not make them inappropriate. The concern is whether the preparation extracted relevant substances or produced material degradation, precipitation, or other changes that undermine interpretation.

For example, cutting a coated catheter may expose internal layers that normally have limited patient contact. Heating a polymer beyond suitable extraction conditions may change its chemistry. Conversely, an extraction that leaves a patient-contacting surface inaccessible may miss a relevant hazard. Each issue requires a device-specific explanation.

Inspect observations such as discoloration, particles, pH changes, or unusual extract appearance. These are investigative clues, not proof of the sensitizing agent. Review extraction blanks and laboratory handling to assess possible contamination from vessels, closures, transfer equipment, or preparation materials.

Do not use a milder extraction in a repeat study simply because it is more likely to produce a negative result. Any change needs a scientific rationale that explains how the new preparation answers the biological safety question.

Trace the finished device, not just its main material

A familiar base polymer or implant alloy does not establish the sensitization profile of the finished product. Processing aids, additives, adhesives, coatings, cleaning residues, and degradation products can change what reaches the patient.

Build a material-and-process map from incoming components through packaging and sterilization. Compare the tested lot with earlier representative lots, supplier specifications, and change records. Give particular attention to substances that can remain on patient-contacting surfaces or migrate into them.

Supplier documentation helps establish hypotheses, but it may not describe every low-level constituent relevant to sensitization. A declaration that a material is suitable for medical use does not resolve a positive result from the finished device.

Separate plausible sources from demonstrated causes. An adhesive residue becomes a stronger hypothesis when it is detected in the affected device, linked to a process deviation, and reduced through a controlled correction.

Use chemical characterization to narrow the investigation

Chemical characterization can help connect a biological response to substances released from the device. It is most useful when designed around specific questions: What differs between affected and reference lots? Is a suspected residual present? Did sterilization introduce or increase a constituent?

Choose analytical methods that suit the suspected chemicals and device materials. Organic screening alone may not address metal-related concerns. A broad screening method may also miss a reactive, unstable, or poorly detected constituent. Where a credible candidate emerges, targeted analysis may provide more useful evidence than another general screen.

Compare results with extraction blanks and suitable reference samples. Establish whether a detected substance originated from the device, packaging, or laboratory process before treating it as a root cause. Analytical identification confidence and measurement limitations should remain visible in the investigation record.

Toxicological assessment then considers the substance’s identity, sensitization evidence, likely patient exposure, contact route, and duration. Sensitization needs endpoint-specific reasoning: an exposure level acceptable for systemic toxicity does not automatically address allergy. Likewise, a general screening threshold should not be treated as a universal safe limit for sensitizers.

Failure to identify a known sensitizer does not cancel a valid positive biological test. Unknown constituents, analytical blind spots, and mixture effects may leave uncertainty. The biological and chemical findings need a coherent explanation together.

Choose follow-up work that can change the decision

Before commissioning another study, write down the hypothesis, the evidence required, and how each possible result would affect the investigation. This prevents repeated testing from becoming a substitute for understanding the failure.

• If a laboratory error is demonstrated: Correct it and determine whether repeating the affected work is necessary. Retain the original study and the justification for its interpretation.
• If contamination is suspected: Investigate its source using appropriate blanks, retained samples, or targeted analysis before selecting additional biological testing.
• If a manufacturing residue is implicated: Correct the process and verify residue reduction before evaluating representative corrected devices.
• If irritation complicates interpretation: Seek a method-specific assessment and select follow-up work that can distinguish the competing explanations.
• If the result remains valid and unexplained: Continue the hazard investigation and reconsider materials or processing rather than treating a negative repeat as closure.

Alternative methods may help clarify mechanisms or assess candidate chemicals, but suitability depends on the sample, the endpoint, and the method’s limitations. A device extract can be a complex mixture that behaves differently from the individual substances used to establish a method’s performance.

Any additional animal testing needs a clear scientific purpose and consideration of suitable alternatives. Repeating a valid positive study solely to obtain a different outcome adds little useful evidence.

Separate corrective action from the release decision

A corrective action addresses the cause; release requires evidence that the resulting device has an acceptable biological safety profile. These decisions are connected, but they are not interchangeable.

If incomplete curing is implicated, tightening the curing process may be appropriate. Verification should establish that the process consistently controls the relevant residuals and that finished-device evaluation addresses the original concern. If a formulation constituent is responsible, additional washing may be ineffective when that constituent continues to migrate from the material.

Evaluate consequences beyond sensitization when changing the device. A new cleaning agent, adhesive, coating, or sterilization process may affect other biological endpoints or functional performance. Select the scope of reevaluation from the actual change and its risks rather than automatically repeating every previous test.

Clinical exposure also affects the assessment. An adhesive dressing on compromised skin, a temporary blood-contacting catheter, and a permanent implant present different exposure conditions. A positive laboratory result does not quantify patient allergy incidence, while an absence of reported complaints provides limited reassurance when reactions may be difficult to recognize or attribute.

Close with an evidence-based explanation

The investigation report should connect the original observation, study validity, causal evidence, corrective actions, and remaining uncertainty. Update the biological evaluation and risk-management documentation using the applicable ISO 10993 framework, and assess any regulatory implications of the finding or resulting changes.

A defensible closure explains why the positive result occurred, or clearly establishes how the unresolved hazard has been controlled and assessed. It identifies the affected scope, shows that corrective actions work, and states the evidence supporting product disposition.

Before authorizing release, ask one practical question: could an independent reviewer follow the evidence from the original positive result to the final safety decision? If the explanation depends mainly on a later negative test, the investigation still has a gap.